Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.2 EUR | -0.64% | +11.51% | +44.86% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Business Summary
- Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors;
- OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors;
- OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia;
- FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes);
- BI 765063/BI 770371 (anti-SIRP? mAb): partnership with Boehringer Ingelheim in advanced solid tumors;
- OSE-230 (ChemR23 agonist mAb): partnership with AbbVie in chronic inflammation.
OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms:
- Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I;
- Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO;
- Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.
Number of employees: 62
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research and Development on Pharmaceutical Products
100.0
%
| 18 | 100.0 % | 2 | 100.0 % | -87.83% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 18 | 100.0 % | 2 | 100.0 % | -87.83% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 16-05-30 |
Director of Finance/CFO | - | 16-04-30 | |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-19 |
Chief Operating Officer | - | 21-12-19 | |
Maryvonne Hiance
BRD | Director/Board Member | 75 | 16-05-30 |
Thomas Guillot
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | - | |
Sophie Fay
PRN | Corporate Officer/Principal | - | - |
Françoise Bono
PRN | Corporate Officer/Principal | - | 21-12-19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Director/Board Member | 66 | 23-06-21 | |
Director/Board Member | 66 | 22-02-17 | |
Didier Hoch
BRD | Director/Board Member | 68 | 16-05-30 |
Maryvonne Hiance
BRD | Director/Board Member | 75 | 16-05-30 |
Gérard Tobelem
BRD | Director/Board Member | 76 | 14-04-09 |
Director of Finance/CFO | - | 16-04-30 | |
Brigitte Dreno
BRD | Director/Board Member | 71 | 17-06-13 |
Director/Board Member | 42 | 21-06-23 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 16-05-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 21,651,101 | 15,675,925 ( 72.40 %) | 70,095 ( 0.3237 %) | 72.40 % |
Company contact information
OSE Immunotherapeutics SA
22, Boulevard Benoni Goullin
44000, Nantes
+33 2 28 29 10 10
http://www.ose-immuno.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+44.86% | 144M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- OSE Stock
- Company OSE Immunotherapeutics